📈 Economy
· Tomorrow
Abbott Laboratories (NYSE: ABT) beats Q2 2026 adjusted Non-GAAP EPS consensus of $1.28 per share (16 July 2026)
Probability
65%
Abbott reports on 16 July 2026 before market open. Consensus is $1.28 Non-GAAP; company guidance range is $1.25–$1.31 per share, midpoint exactly at consensus. Abbott has beaten consensus in eight consecutive quarters. FreeStyle Libre revenue grows ~15–18% YoY, driving the medical devices segment. Diagnostics segment continues to benefit from post-pandemic test infrastructure. No Polymarket quote; historical beat rate ~72% (FactSet tracking).
Data basis for this prediction
- Alphastreet: ABT Q2-2026 Earnings Preview – Non-GAAP EPS Konsens $1,28, Guidance $1,25–$1,31 (15.07.2026)
- StockTitan: Abbott Earnings Conference Call angesetzt für 16. Juli 2026, 9 Uhr ET (Meldung Juli 2026)
- Abbott Q2 2025 Non-GAAP EPS: $1,17 – 8 aufeinanderfolgende Quartale über Konsens (Abbott IR, Juli 2025)
- FreeStyle Libre YoY-Wachstum ~15–18 % in 2025/2026 (Abbott Investor Presentations)
Note: This is an AI-generated statistical forecast for entertainment and information purposes. It does not constitute investment advice or a recommendation to buy or sell any financial instrument.
Verdict: Pending
This prediction is still open. It will be evaluated automatically against real-world sources after its due date.